Table 3. Summary of miRs with altered expression, their potential targets and pathways entered this study.
| microRNA | Expression | Potential target | Pathway | Reference |
|---|---|---|---|---|
| miR-210 | Up | ISCU1/2, HIF | VHL/HIF/hypoxia pathway | 20,23,24,27,28,30,31 |
| miR-21 | Up | P53, TGF-β, VHL, EGLN1, PTEN, TSC1, TSC2, PDCD4, | Cell cycle control/proliferation, migration and invasion, mitochondrial apoptosis pathway | 21,22,26,27,31 |
| miR-486 | Up | PTEN, OLFM4, FOXO1 | Cell adhesion and migration | 45 |
| miR-1260b | Up | sFRP1, Dkk2, Smad4 | Cell proliferation, apoptosis, invasion | 32 |
| miR-100 | Up | mTOR | Cell proliferation | 33 |
| miR-125b | Up | E2F3, P53, BAK1, MMP9 | Cell growth, apoptosis, metastasis | 34 |
| miR-221 | Up | PTEN, TIMP3, c-Kit, p21, p53, p57 | Cell cycle, proliferation, apoptosis, migration, invasion, EMT, EGFR signaling pathway | 25,27 |
| miR-222 | Up | PTEN, TIMP3, c-Kit, p21 | Cell cycle, migration, invasion, EMT | 25 |
| miR-630 | Up | IGF-1R | Cell death and apoptosis | 35 |
| miR-497 | Up | IGF-1R | Cell proliferation, migration, invasion | 36 |
| miR-106b | Down | TGF-β signaling | TGF-β signaling | 37 |
| miR-99a | Down | mTOR | Cell growth/cycle control, migration and invasion, mTOR pathway | 38 |
| miR-1826 | Down | CTNNB1, MEK1 | Cell proliferation, invasion, migration, apoptosis | 39 |
| miR-215 | Down | MDM2, ZEB2, TYMS | Cell migration, invasion, proliferation | 40 |
| miR-217 | Down | SirT1, KRAS | Cell proliferation, migration | 41 |
| miR-155 | Down | SOCS1, SHIP1, TP53INP1 | Apoptosis-related signaling, hypoxia pathway | 46 |
| miR-187 | Down | B7-H3, Dab2 | Cell growth, migration, EMT | 42 |
| miR-129–3p | Down | SOX4, p-FaK, MMP2, MMP9 | Cell migration, invasion | 43 |
| miR-23b/27b | Down | cytokine interaction pathway | Cell proliferation, migration and invasion | 44 |
| miR-126 | Down | SPRED1, IGF1R, BCL2, CRK, CCNE2, PIK3R2, EGFL7 | Apoptosis, HIF-1, VEGF, mTOR, and PI3K-Akt signaling pathways | 26,27,29 |
HIF = hypoxia inducible factor; PTEN = phosphatase and tensin homologue; TGF = transforming growth factor; mTOR = mammalian target of rapamycin; TSC = tuberous sclerosis; MMP = matrix metalloproteinase; TIMP = tissue inhibitor of metalloproteinase; EMT = epithelial-to-mesenchymal transition; EGFR = epidermal growth factor receptor; IGF = insulin-like growth factor; VEGF = vascular endothelial growth factor.